Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin + bortezomib + dexamethasone in double-refractory multiple myeloma
2015-003486-29Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by PharmaMar. Primary endpoint: Overall response rate. Started Aug 2016; status: terminated.
02
Drugs
plitidepsinbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-003486-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003486-29.